文献速递腹部US

基于肿瘤大小的CEUS LI-RADS 2017对肝细胞癌诊断效能的验证

Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.
PubMed 文献 · Br J Radiol · 2021-01-01

本研究纳入545个未经治疗的肝结节,按大小分为<20 mm和≥20 mm两组,验证CEUS LI-RADS 2017对高危患者肝细胞癌的诊断效能。结果显示LR-5标准诊断HCC的效能两组无显著差异,但LR5/M诊断恶性病变的效能≥20 mm组优于<20 mm组。

要点

  • CEUS LR-5诊断HCC的效能不受结节大小影响。
  • LR5/M诊断恶性病变时≥20 mm组效能更高。
  • 小肝癌(<20 mm)诊断敏感度相对较低。

核心结论

  • CEUS LI-RADS对≥20 mm和<20 mm结节诊断HCC的效能相当。
  • 对于包括HCC在内的恶性病变诊断,≥20 mm结节的效能高于<20 mm结节。

研究设计与样本

  • 结节按大小分为<20 mm组和≥20 mm组,依据CEUS LI-RADS进行分类,采用卡方检验比较诊断效能。

诊断标准与关键数值

  • LR-5标准诊断HCC:<20 mm组准确度60.5%、敏感度55.6%、特异度85.7%、PPV 95.2%;≥20 mm组分别为59.8%、57.6%、88.6%、98.5%,两组差异均无统计学意义(均p>0.05)。
  • LR5/M诊断恶性病变:<20 mm组准确度79.1%、敏感度84.2%、PPV 91.4%;≥20 mm组分别为95.0%、95.7%、99.2%,两组差异有统计学意义(p<0.05)。

临床应用与阅片要点

  • 日常阅片中可依据CEUS LI-RADS对高危患者肝结节进行分类,LR-5提示HCC。
  • 对于<20 mm结节,LR5/M诊断恶性病变的效能较低,需结合其他影像或随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To validate the efficacy of contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) and its major features in diagnosing hepatocellular carcinoma (HCC) of different sizes in high-risk patients.

METHODS: Between January 2014 and December 2015, a total of 545 untreated liver nodules were included. These liver nodules were divided into two groups (<20 mm and ≥20 mm). Each nodule was classified based on CEUS LI-RADS. The diagnostic performance comparison was assessed by the chi-square test, with pathology results as the golden criterion.

RESULTS: The accuracy, sensitivity, specificity, and positive predictive value (PPV) of CEUS LR-5 criteria in <20 mm group vs ≥20 mm group in diagnosing HCC were 60.5% vs 59.8%, 55.6% vs 57.6%, 85.7% vs 88.6 and 95.2% vs 98.5%, respectively, without significant difference (all p > 0.05). The accuracy, sensitivity and PPV of LR5/M for malignancy in <20 mm group were lower than in ≥20 mm group, with values of 79.1% vs 95.0%, 84.2% vs 95.7 and 91.4% vs 99.2%, respectively (p < 0.05).

CONCLUSIONS: The CEUS LI-RADS has a comparable performance for diagnosing HCC between lesions ≥ 20 mm and <20 mm. For diagnosing malignancy including HCC, it has a higher efficacy for lesions ≥ 20 mm than <20 mm.

ADVANCES IN KNOWLEDGE: 1.For diagnosing HCC, CEUS LI-RADS has comparable performances between lesions ≥ 20 mm and <20 mm.2. For diagnosing malignancy including HCC, CEUS LI-RADS has a higher efficacy for lesions ≥ 20 mm than <20 mm.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Pan JM, Chen W, Zheng YL, et al. Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing. Br J Radiol. 2021. PMID: 34545763. doi:10.1259/bjr.20201359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。